Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.45 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.45 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.45 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.45 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4674257 | 0.89 | IKBKB (0.57) | IKBKBROCK1PRKCZHRH1PDE10A | |
| Hydrochloric Acid SCHEMBL18318430 | 0.88 | IKBKB (0.48) | IKBKBROCK1PRKCZHRH1HTR6 | |
| Hydrochloric Acid SCHEMBL23360382 | 0.87 | IKBKB (0.56) | IKBKBROCK1PRKCZHRH1PDE10A | |
| SCHEMBL11063126 | 0.80 | IKBKB (0.68) | IKBKBROCK1PRKCZHRH1ROCK2 | |
| Hydrochloric Acid SCHEMBL7452746 | 0.79 | IKBKB (0.66) | IKBKBROCK1PRKCZHRH1ROCK2 | |
| SCHEMBL19852514 | 0.78 | PDE10A (0.53) | ROCK1HRH1PDE10APDE3BPDE3A | |
| SCHEMBL5020201 | 0.77 | ALDH1A1 (0.51) | IKBKBROCK1PDE10APDE3BPDE3A | |
| SCHEMBL12505400 | 0.77 | IRAK4 (0.49) | IKBKBROCK1HRH1SLC6A2SLC6A3 | |
| SCHEMBL357765 | 0.77 | IRAK4 (0.41) | IKBKBROCK1HRH1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL12505351 | 0.76 | IRAK4 (0.48) | IKBKBROCK1HRH1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-7307090-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | disclosed |
| US-7265227-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-09-04 | — | — | US | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| EP-1404667-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1604982-A1 | INTERMEDIATES FOR THE PREPARATION OF PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | IKBKB 2529/4885ROCK1 2401/4885PRKCZ 3152/4885 |
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | IKBKB 782/4885ROCK1 1642/4885PRKCZ 4468/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | IKBKB 2529/4885ROCK1 2401/4885PRKCZ 3152/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | IKBKB 782/4885ROCK1 1642/4885PRKCZ 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.